Drug discovery- AEBI

• AEBi is a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic peptides. AEBi has developed “SoAP”, a combinatorial biology screening platform technology.

• Using SoAP, AEBi can develop drugs to many illnesses. This technology will significantly accelerate the drug discovery R&D phase and reduce attrition rate of new drug candidates.

• The advantage of the technology is that it generates very specific lead compounds with a great functionality, and improved pharmacological properties. Such lead compounds should give very effective drugs, with the smallest side effects.

• In 2010n AEBi has been involved in two cancer projects. The leading one was using Epidermal Growth Factor Receptor (EGFR) as a target. AEBI have found many leads that were proven to be functionally positive.

• The second project AEBI is involved in uses Insulin like Growth Factor Receptor (IGFR) as a target. The company already got positive clones, and is in the process of isolating more hits.

• Regarding Peptides short life cycle: AEBi decided to choose a generic strategy to substantially increase our peptides half lives in blood. The chosen method was to attach the peptides to a Polyethylene glycol (PEG) molecule.

Aviation

Urban Aeronautics Ltd - is developing a family of Vertical-Takeoff-and-Landing (VTOL), utility aircraft with internal (ducted fan) lift rotors. These aircraft, known as ‘Fancraft’™, are capable of safely carrying out a vast range of groundbreaking missions in confined areas. Fancraft™ are designed to in accordance with current Federal Aviation Administration (FAA) certification standards